TickerFacts.

Zenas BioPharma, Inc. (ZBIO): Shareholders' Equity

Annual figures by period end, from SEC filings.

$242.14M
As of 2025-12-31
$247.10M
As of 2026-06-30
$312.46M2023-12-31: -$225.72M2024-12-31: $312.46M2025-12-31: $242.14M$242.14M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$242.14M-22.5%2026-03-16, Balance as of period end
2024-12-31$312.46Mn/m2026-03-16, Balance as of period end
2023-12-31-$225.72Mn/a2025-03-11, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Zenas BioPharma, Inc. (ZBIO)2025-12-31$242.14M-22.5%
Janux Therapeutics, Inc. (JANX)2025-12-31$956.82M-6.4%
Precigen, Inc. (PGEN)2025-12-31$20.91M-45.7%
Prothena Corp Public Ltd Co (PRTA)2025-12-31$280.47M-42.4%
Crescent Biopharma, Inc. (CBIO)2025-12-31$203.01Mn/m
International Stem Cell Corp (ISCO)2025-12-31-$4.06Mn/m
BioAge Labs, Inc. (BIOA)2025-12-31$272.05M-15.8%
Jaguar Health, Inc. (JAGX)2025-12-31-$18.69Mn/m
Roivant Sciences Ltd. (ROIV)2026-03-31$4.53B-3.4%

Compare ZBIO, JANX, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗